Quadruplet Induction Regimen in Newly Diagnosed Multiple Myeloma

Panelists discuss whether daratumumab quadruplet induction regimens should be considered the new standard of care for newly diagnosed transplant-eligible patients and explore scenarios in which a triplet induction regimen might still be appropriate. They also review the findings from the ISKIA and GMMG-CONCEPT trials, including considerations for using isatuximab-carfilzomib (IsaKRd) over D-VRd.

EP: 1.Transplant Eligible, Newly Diagnosed Multiple Myeloma: PERSEUS & CASSIOPEIA Study Updates

Now Viewing

EP: 2.Quadruplet Induction Regimen in Newly Diagnosed Multiple Myeloma

EP: 3.Transplant-ineligible Patients with Newly Diagnosed Multiple Myeloma: CEPHEUS, IMROZ, and BENEFIT Studies

EP: 4.MRD Negativity as a Trial Outcome and Its Use in Clinical Practice

EP: 5.Use of CAR T-cell Therapies for Early Relapse Multiple Myeloma

EP: 6.Considerations for Triplet or Quadruplet Regimens in Transplant-ineligible Patients with Newly Diagnosed Multiple Myeloma

EP: 7.Considerations for Use of CAR T-cell Therapy in Multiple Myeloma

EP: 8.CAR T-cell Therapies for Multiple Myeloma: KarMMa-3 and CARTITUDE-4 Study Updates at IMS 2024

EP: 9.Insights from IMS 2024 on Counseling Patients with Multiple Myeloma about CAR T-cell Therapy and Connecting to Referral Centers

EP: 10.Importance of Early Referral for CAR T-cell Therapy in Multiple Myeloma and Patient Quality of Life

1. In your clinical opinion, are daratumumab quadruplet induction regimens the new standard of care for newly diagnosed (transplant-eligible) patients? Are there patients for whom you would still consider a triplet induction regimen?
2. Could you also review the ISKIA & GMMG-CONCEPT trials and findings? Are there any clinical scenarios where you would consider an isatuximab-carfilzomib (IsaKRd) quadruplet over D-VRd?

Related Videos